Benchmark Downgrades Xoma to Hold After $39 Acquisition Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Benchmark analyst Robert Wasserman downgraded Xoma (XOMA) to Hold from Buy after Ligand Pharmaceuticals (LGND) announced a definitive agreement to acquire Xoma for $39 per share in cash.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 41.700
Low
50.00
Averages
71.00
High
97.00
Current: 41.700
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, Organon & Co., and Veris Residential, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with transaction prices at $39.00, $14.00, and $19.00 per share respectively, indicating potential threats to shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to provide legal services on a contingency fee basis, aiming to secure higher transaction prices and additional disclosures for affected investors, thereby enhancing legal protections for shareholders.
- Potential Impact: The investigation may lead to a reassessment of transaction terms, particularly those that could limit superior competing offers, and if successful, could yield greater financial benefits for shareholders, reflecting a commitment to corporate governance and transparency.
- Legal Service Commitment: Halper Sadeh LLC states it will represent investors globally in seeking legal remedies, having previously recovered millions for victims of securities fraud, showcasing its expertise and influence in addressing corporate misconduct.
See More
Investigations into Multiple Company Acquisitions
- Veris Acquisition Investigation: Veris Residential, Inc. is set to be acquired by Affinius Capital for $19.00 per share, representing an enterprise value of $3.4 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- XOMA Transaction Scrutiny: XOMA Royalty Corporation will be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million, with investigations questioning whether the board ensured fair value for shareholders, especially as the offer is below the 52-week high of $42.38.
- Organon Acquisition Concerns: Organon & Co. is to be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and investigations are looking into whether the board failed to conduct a fair process, which could harm shareholder interests.
- RE/MAX Transaction Investigation: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations questioning whether the board ensured the fairness of the transaction, potentially affecting shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and fiduciary duties, which may impact shareholder rights.
- Select Medical Transaction: Shareholders of Select Medical may face a sale to a consortium led by executives at $16.50 per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- XOMA Royalty Transaction: XOMA Royalty Corporation shareholders are set to sell to Ligand Pharmaceuticals for $39.00 per share, and Halper Sadeh LLC may advocate for higher transaction prices and transparency to ensure shareholders' legal rights are upheld.
- Soleno and KORE Transactions: Soleno Therapeutics shareholders will sell to Neurocrine Biosciences for $53.00 per share, while KORE Group Holdings shareholders will sell to Searchlight Capital Partners and Abry Partners for $9.25 per share, with Halper Sadeh LLC providing legal support to ensure these shareholders' rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and Galera Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholders' financial interests.
- XOMA Transaction Details: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, a transaction that may limit the emergence of superior competing offers, thereby affecting shareholders' options.
- RE/MAX Shareholder Choices: Shareholders of RE/MAX Holdings, Inc. can choose to sell their shares for either 5.152 shares of the combined company or $13.80 in cash per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to ensure fair treatment.
- Galera Merger Impact: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, Organon & Co., and Veris Residential, Inc. for potential violations of federal securities laws and breaches of fiduciary duties to shareholders, with transaction prices at $39.00, $14.00, and $19.00 per share respectively, indicating potential threats to shareholder rights.
- Shareholder Rights Protection: The law firm encourages shareholders to contact them to discuss their rights and options, promising to provide legal services on a contingency fee basis, aiming to secure higher transaction prices and additional disclosures for affected investors, thereby enhancing legal protections for shareholders.
- Potential Impact: The investigation may lead to a reassessment of transaction terms, particularly those that could limit superior competing offers, and if successful, could yield greater financial benefits for shareholders, reflecting a commitment to corporate governance and transparency.
- Legal Service Commitment: Halper Sadeh LLC states it will represent investors globally in seeking legal remedies, having previously recovered millions for victims of securities fraud, showcasing its expertise and influence in addressing corporate misconduct.
See More
Investigations into Multiple Company Acquisitions
- Veris Acquisition Investigation: Veris Residential, Inc. is set to be acquired by Affinius Capital for $19.00 per share, representing an enterprise value of $3.4 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- XOMA Transaction Scrutiny: XOMA Royalty Corporation will be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million, with investigations questioning whether the board ensured fair value for shareholders, especially as the offer is below the 52-week high of $42.38.
- Organon Acquisition Concerns: Organon & Co. is to be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and investigations are looking into whether the board failed to conduct a fair process, which could harm shareholder interests.
- RE/MAX Transaction Investigation: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations questioning whether the board ensured the fairness of the transaction, potentially affecting shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies like Select Medical Holdings, XOMA Royalty Corporation, Soleno Therapeutics, and KORE Group Holdings for potential violations of federal securities laws and fiduciary duties, which may impact shareholder rights.
- Select Medical Transaction: Shareholders of Select Medical may face a sale to a consortium led by executives at $16.50 per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures to protect shareholder interests.
- XOMA Royalty Transaction: XOMA Royalty Corporation shareholders are set to sell to Ligand Pharmaceuticals for $39.00 per share, and Halper Sadeh LLC may advocate for higher transaction prices and transparency to ensure shareholders' legal rights are upheld.
- Soleno and KORE Transactions: Soleno Therapeutics shareholders will sell to Neurocrine Biosciences for $53.00 per share, while KORE Group Holdings shareholders will sell to Searchlight Capital Partners and Abry Partners for $9.25 per share, with Halper Sadeh LLC providing legal support to ensure these shareholders' rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Helix Energy Solutions Group, Inc. and Hornbeck Offshore Services, Inc., with Helix shareholders expected to own approximately 45% of the combined entity, potentially impacting shareholder rights and future earnings.
- Acquisition Review: Organon & Co. is being sold to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek increased compensation and additional disclosures to ensure shareholder rights are protected.
- Equity Transaction: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC representing shareholders to investigate the compliance of this transaction and ensure fair terms for shareholders.
- RE/MAX Deal: RE/MAX Holdings, Inc. is in a transaction with The Real Brokerage Inc., allowing shareholders to choose either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC providing legal support to safeguard shareholder interests.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and Galera Therapeutics, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholders' financial interests.
- XOMA Transaction Details: XOMA Royalty Corporation is being sold to Ligand Pharmaceuticals Incorporated for $39.00 per share, a transaction that may limit the emergence of superior competing offers, thereby affecting shareholders' options.
- RE/MAX Shareholder Choices: Shareholders of RE/MAX Holdings, Inc. can choose to sell their shares for either 5.152 shares of the combined company or $13.80 in cash per share, with Halper Sadeh LLC encouraging shareholders to understand their rights and options to ensure fair treatment.
- Galera Merger Impact: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures to protect shareholder interests.
See More
Investigation Alerts for Multiple Company Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to uphold fiduciary duties to ensure a fair process for shareholders.
- RE/MAX Merger Investigation: RE/MAX Holdings, Inc. is being acquired by The Real Brokerage Inc., allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash, with investigations looking into whether the Board adequately handled the transaction to protect shareholder interests.
- Soleno Acquisition Case: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total equity value of approximately $2.9 billion, while the investigation questions whether the Board ensured the deal was fair to shareholders, given that the price is below its 52-week high of $90.32.
See More
